Swedbank AB Grows Position in Illumina, Inc. $ILMN

Swedbank AB raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 57.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 825,491 shares of the life sciences company’s stock after buying an additional 301,806 shares during the quarter. Swedbank AB owned about 0.54% of Illumina worth $78,397,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Optas LLC purchased a new stake in Illumina in the 3rd quarter worth about $215,000. Farther Finance Advisors LLC boosted its stake in shares of Illumina by 12.0% during the third quarter. Farther Finance Advisors LLC now owns 2,824 shares of the life sciences company’s stock valued at $268,000 after purchasing an additional 303 shares in the last quarter. Parcion Private Wealth LLC lifted its holdings in Illumina by 17.9% during the third quarter. Parcion Private Wealth LLC now owns 4,580 shares of the life sciences company’s stock worth $435,000 after buying an additional 694 shares during the period. Kaufman Rossin Wealth LLC boosted its position in Illumina by 4.3% during the 3rd quarter. Kaufman Rossin Wealth LLC now owns 4,851 shares of the life sciences company’s stock valued at $461,000 after acquiring an additional 198 shares in the last quarter. Finally, Brighton Jones LLC boosted its position in Illumina by 20.1% during the 3rd quarter. Brighton Jones LLC now owns 16,030 shares of the life sciences company’s stock valued at $1,522,000 after acquiring an additional 2,686 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Illumina news, Director Scott Gottlieb purchased 500 shares of the stock in a transaction dated Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.60% of the company’s stock.

Illumina Trading Up 0.2%

Illumina stock opened at $136.43 on Thursday. The firm has a market cap of $20.85 billion, a PE ratio of 30.59, a P/E/G ratio of 2.44 and a beta of 1.44. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The stock’s 50 day simple moving average is $120.85 and its two-hundred day simple moving average is $105.62. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company posted $1.14 EPS. The business’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ILMN. Barclays upped their price objective on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Robert W. Baird set a $109.00 price target on shares of Illumina in a research report on Friday, October 31st. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. Cowen reiterated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $118.31.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.